New Apple Tree biotech emerges with antibodies that might pair with Amgen, Mirati's KRAS drugs,Apple Tree Partners is out Monday with a new biotech from the labs of NYU Langone Health that aims to tackle drug resistance in cancer. Aethon Therapeutics will get $25 million from the VC firm, and another $5 million from New York University and other investors, the New York-based biotech
New Apple Tree biotech emerges with antibodies that might pair with Amgen, Mirati’s KRAS drugs
Apple Tree Partners is out Monday with a new biotech from the labs of NYU Langone Health that aims to tackle drug resistance in cancer. Aethon Therapeutics will get $25 million from the VC firm, and another $5 million from New York University and other investors, the New York-based biotech
Bayonetta Origins: Cereza And The Lost Demon | New Gameplay Today,We take a tour of Bayonetta's wonderfully charming origin story. Tags:gameinformer.comGamesNGT
Boundary Zero-G FPS Comes to Steam Early Access on April 13th,Studio Surgical Scalpels and Skystone Games announced that the zero-G first-person shooter Boundary will launch on April 13 via Steam EA. Tags:wccftech.com
Review: Atelier Ryza 3: Alchemist of the End & the Secret Key (PS5) - Huge RPG Is Familiar But Charming,Farewell party Tags:Push Squarepushsquare.comreviews
Apple again tipped to bid for Premier League rights,Apple has once again been tipped to bid for Premier League footballrights when they come around again in 2025 Tags:tech newstrustedreviews.comTV
Open World Racing Lego 2K Drive Revealed, Releasing This May,This is the first game of a multi-title partnership between Lego and 2K. Tags:gameinformer.comGamesNews
EU to launch vaccine development and manufacturing partnership with Latin American and Caribbean countries,While European companies, including BioNTech, are focused on increasing vaccine access to African countries by setting up vaccine manufacturing facilities, the European Union is looking westward to Latin America and the Caribbean. Speaking at a press conference with Spanish Prime Minister Pédro Sanchez, president of the EU Commission Ursula von Tags:Business and HealthEndpoints Newsendpts.comfinancingManufacturingNews
ViiV takes to the couch for conversations about HIV in its new ‘Science on the Sofa’ series,ViiV takes to the couch for conversations about HIV in its new ‘Science on the Sofa’ series,ViiV Healthcare is cozying up on the couch to talk about HIV science. Its new “Science on the Sofa” series talks cures, undetectable equals untransmissible (U=U) and other sometimes complex scientific concepts with ViiV researchers, HIV patients and advocates. The three-video series in Season 1, out now, is posted on Tags:Business and HealthEndpoints Newsendpts.comMarketingNewsPharmapopular
Aiming at mainstream markets, radiopharmaceutical partners engineer $260M cash deal,When Point Biopharma geared up to launch a Phase III trial for its PSMA-targeting radioligand therapy, one of the first things it did was to partner with Lantheus, the maker of a then-investigational PET imaging agent that can visualize the presence of the prostate-specific membrane antigen in patients. Two years Tags:Business and HealthDealsEndpoints Newsendpts.comFeaturedNews
Three biotechs start the year with job cuts; Regeneron expands deal with bluebird spinout,Elevation Oncology’s CEO and founder is stepping down immediately as the company abandons its former lead candidate and chops 30% of its workforce. The company announced Shawn Leland’s abrupt resignation Friday morning, as well as plans to pause further investment on seribantumab, the drug it revived from Merrimack in 2020. Tags:Business & HealthEndpoints Newsendpts.comNews Briefing
Real Chemistry's holiday gift to clients: fighting hate speech,Real Chemistry's holiday gift to clients: fighting hate speech,Real Chemistry is fighting hate speech this holiday season with the help of a browser extension that replaces offensive language with heart-healthy cooking recipes. The project is part of the healthcare company’s annual holiday campaign, delivered to clients’ inboxes in the form of a greeting card. Last season, the team Tags:Business and HealthEndpoints Newsendpts.comMarketingNewsPharmaTrending
Billionaire-backed TCR startup scores its first marquee industry alliance,SAN FRANCISCO — A Bay Area startup out to create a next-gen player in TCRs has just hit a key milestone following its recent debut, inking its first big alliance with a big-name pharma while also bringing in some added insights from clinical operations that can help shape their work. Tags:Business & HealthEndpoints Newsendpts.comR&D
Vanda loses Hetlioz patent court decision, vows to appeal and ask for stay on Teva, Apotex competitors,Vanda loses Hetlioz patent court decision, vows to appeal and ask for stay on Teva, Apotex competitors,A federal judge invalidated four of Vanda Pharmaceuticals' patents for sleep med Hetlioz on Tuesday, effectively opening the door to generic tasimelteon competition from Teva, Apotex and others. Vanda plans to appeal and is asking for a stay against the competition in the meantime. “Vanda intends to appeal the decision Tags:Business and HealthEndpoints Newsendpts.comLAWNewsPharma
Jasper scraps pivotal plans but adds a new indication as more biotechs revise pipelines,A suite of biopharmas disclosed cuts to their pipelines this week as the industry gets a sweeping update of drugs in the works as part of the annual JP Morgan Healthcare Conference. Jasper Therapeutics, Acticor Biotech, NGM Bio and Annexon were among those to slash parts of their development plans. Tags:Business & HealthEndpoints Newsendpts.comR&Dstartups
AstraZeneca to discontinue rare blood cancer drug in the US,AstraZeneca is retiring Lumoxiti, its third-line treatment for a rare type of blood cancer called hairy cell leukemia (HCL), the company confirmed to Endpoints News on Thursday. The drug will be permanently discontinued in the US as of July 2023, in part due to competition from rivals, a spokesperson said Tags:Business & HealthEndpoints Newsendpts.comFDAPharma
Three Ohio-based contract organizations win $149M deal for neurological candidates,Three contract organizations based near the capital of Ohio are starting the year with a multimillion-dollar deal. The science and technology company Battelle, contract researcher AmplifyBio and CDMO Andelyn Biosciences have netted an eight-year, $149 million indefinite delivery, indefinite quantity contract from the National Institute of Neurological Disorders and Stroke Tags:Business & HealthDealsEndpoints Newsendpts.comManufacturingoutsourcing
Scoop: Just months after Sanofi AI deal, Atomwise laid off 30% of staffers amid 'strategic shift',Atomwise, a well-connected player in the burgeoning space of artificial intelligence-powered drug discovery, cut its headcount by 30% in December, Endpoints News has learned. CEO and co-founder Abraham Heifets confirmed the layoffs, which resulted in around 30 people departing the company. “We had to make some very hard decisions and Tags:Business & HealthEndpoints Newsendpts.comPEOPLEpremium
J&J quietly punts a pair of early-stage bispecifics for solid tumors,Johnson & Johnson has put two early-stage bispecific antibodies on the backburner, the pharma giant revealed as part of its quarterly update. Listed in the pipeline as recently as October, JNJ-6358 — a bispecific antibody binding to CD3 on T cells and human leukocyte antigen G (HLA-G) on cancer cells Tags:Business & HealthEndpoints Newsendpts.comPharmaR&D
Amgen lays off about 300 workers, citing 'industry headwinds',Amgen has laid off about 300 employees, a company spokesperson confirmed to Endpoints News via email Sunday night. Employees posted to LinkedIn in recent days about layoffs hitting Amgen last week. The Thousand Oaks, CA-based biopharma, which employs about 24,000 people, said the reduction “mainly” impacted US-based workers on its Tags:Business & HealthEndpoints Newsendpts.comPEOPLEPharmapremium
Pfizer brings Ibrance to new subset of breast cancer patients, regardless of menopausal status,Pfizer has expanded Ibrance’s use to include a new subset of breast cancer patients, the company slipped into its quarterly earnings report on Tuesday. The drug was approved in combination with an aromatase inhibitor (AI) in mid-December to treat women with HR-positive, HER2-negative metastatic breast cancer regardless of menopausal status, Tags:Business & HealthEndpoints Newsendpts.comFDAPharma
Inflation rebates incoming: Wyden calls on CMS to move quickly as Novartis CEO pledges reversal,Senate Finance Chair Ron Wyden (D-OR) this week sent a letter to the head of the Centers for Medicare & Medicaid Services seeking an update on how and when new inflation-linked rebates will take effect for drugs that see major price spikes. The newly signed Inflation Reduction Act requires manufacturers Tags:Business & HealthEndpoints Newsendpts.comLAWPharma
Bayer taps Roche's Bill Anderson to lead pharma giant as CEO,We now know where Roche’s ex-pharma chief Bill Anderson is going. German pharma giant Bayer announced Wednesday that Anderson will be taking on the role as CEO, less than six weeks after Anderson stepped down from his perch at Roche as head of the group’s pharmaceutical division. Roche announced back Tags:Business & HealthEndpoints Newsendpts.comPEOPLEPharma
Sesen Bio reaches deal with investor group, paving way for Carisma merger,With a new deal, Sesen Bio's merger with CAR-M player Carisma Therapeutics is finally getting the signal to move forward. The deal, announced Tuesday, was reached with an investor group that currently controls 8.7% of Sesen Bio’s shares. The group, led by Bradley Radoff and Michael Torok, had previously called Tags:Business & HealthDealsEndpoints Newsendpts.comfinancing
Cullinan Oncology drops $25M upfront for candidate from Harbour,Harbour BioMed will be netting eight figures upfront for one of its oncology candidates after signing a deal with Cullinan Oncology. Cullinan will get an exclusive license, including development and commercial rights, from Harbour for its candidate HBM7008 in the US, also known as CLN-418. Cullinan will pay Harbour $25 Tags:Business & HealthDealsEndpoints Newsendpts.comR&D
CMS not ready to reconsider its block on covering new Alzheimer's drugs,The Centers for Medicare and Medicaid Services won't yet reconsider a decision that FDA-approved, amyloid-targeting monoclonal antibodies for Alzheimer’s disease shouldn't be covered outside of clinical trials. The agency's January 2022 ruling, known as a national coverage determination, or NCD, set the precedent for coverage of Biogen's first Alzheimer's drug Tags:Business & HealthEndpoints Newsendpts.comPharma
Full FDA hold derails clinical study of Fulcrum drug in a no good, very bad week for sickle cell R&D,The roller-coaster ride of highs and lows at Cambridge, MA-based Fulcrum Therapeutics just took a sickening plunge. Weeks after using some upbeat results to set the stage for a $125 million raise — no easy feat in this market — the Fulcrum team got hit with a full clinical hold Tags:Business & HealthEndpoints Newsendpts.comFDA
Kymera's top drug hunter leaves for Alexis Borisy's Curie.Bio; What’s done is Dunn: FDA neuroscience leader bows out,By day two of his job as CSO partner at Alexis Borisy’s new investment and biotech services firm, Chris De Savi had already gone through the due diligence with multiple founders looking to get their ideas off the ground and into the experimentation phase. The former Kymera Therapeutics drug discovery Tags:Business & HealthEndpoints Newsendpts.comPeer Review
Moderna selects Oxfordshire for new research and manufacturing site,Moderna has decided on the green fields of Oxfordshire to build its newest research and manufacturing site. Moderna plans to open the site, called the Moderna Innovation and Technology Center (MITC), on the Harwell Science and Innovation Campus, which sits near the village of Harwell, UK, 16 miles south of Tags:Business & HealthEndpoints Newsendpts.comManufacturingPharma
Alnylam expands RNAi commercialization deal in Europe,Alnylam is doubling down on a partnership to expand its commercial presence in Europe, as it forges ahead on former CEO John Maraganore’s mission to become a top-five biotech by the middle of the decade. The company announced on Thursday that it’s expanding a five-year-running commercial partnership with Medison Pharma. Tags:Business & HealthEndpoints Newsendpts.comMarketingPharma
AbbVie-sponsored eczema documentary debuts at South by Southwest,Alexis Smith was tired of being ashamed of her eczema. That’s why, as a 19-year-old in 2016, she posted side-by-side photos of her face with and without makeup. The level of positive outreach she received was “very surprising,” and the eczema advocate continues to document her journey on social media. Tags:Business & HealthEndpoints Newsendpts.comMarketingPharma
Gossamer stops enrollment on BTK inhibitor program, goes all in on PAH drug,Gossamer Bio is stopping enrollment on a Phase Ib/II trial of its BTK inhibitor in CNS lymphoma, it said in its annual report Friday morning. The San Diego-based biotech said, “Based upon the benefit / risk profile observed to date and a prioritization of resources to support the seralutinib program,” Tags:Business & HealthEndpoints Newsendpts.comR&D
Novartis pulls the plug on UK-based cardiovascular study,Novartis is calling off a UK-based trial for Leqvio in the primary prevention of cardiovascular events in patients with high cholesterol, the company confirmed on Wednesday. The Swiss pharma giant made the decision after “careful evaluation,” a spokesperson told Endpoints News via email. The trial, dubbed ORION-17, was planned in Tags:Business & HealthEndpoints Newsendpts.comR&D
J&J's Spravato pulls a PhIII win against Seroquel XR in treatment-resistant depression,J&J's Spravato pulls a PhIII win against Seroquel XR in treatment-resistant depression,A day before Thanksgiving, J&J’s Janssen has a new cut of Phase III Spravato data to be grateful for. The pharma giant announced on Wednesday that its nasal spray, also known as esketamine, beat extended-release quetiapine, previously sold by AstraZeneca as Seroquel XR, in treatment-resistant depression (TRD). Of 676 adults, Tags:Business and HealthEndpoints Newsendpts.comNewspopularR and D
Updated: Teva picks former Sandoz head as new CEO to replace Kåre Schultz,Updated: Teva picks former Sandoz head as new CEO to replace Kåre Schultz,Teva has tapped the former CEO of Sandoz, Richard Francis, to lead the Israeli generics giant, replacing current CEO Kåre Schultz. Francis led Sandoz, the generics division of Novartis, for five years from 2014 to 2019, leaving as Novartis began making plans to spin out the unit. It's been a Tags:Business and HealthEditor's PicksEndpoints Newsendpts.comNewsPEOPLE
In 'miraculous' case, doctors treated a baby with a rare genetic disease before she was born,One of the tenets of pediatric rare diseases is early treatment. For most, that comes after newborn screening — a heel blot soon after a baby is born, with results usually around a week later. If the results suggest a baby has a rare disease, they are directed to start Tags:Business and HealthdiscoveryEndpoints Newsendpts.comNewsR and D
Amolyt hauls in €130M round to fund PhIII trial of hypoparathyroidism drug,French-American biotech Amolyt Pharma has raised a €130 million ($138 million) Series C round, planning to use the cash to take its hypoparathyroidism drug into final-stage testing and move another experimental drug into the clinic. The fundraise, which was led by VC firm Sofinnova Partners, comes less than a year Tags:Business & HealthEndpoints Newsendpts.comfinancing
AbbVie adds depression indication to Vraylar's label months after Gonzalez touts $4B+ peak sales potential,AbbVie adds depression indication to Vraylar's label months after Gonzalez touts $4B+ peak sales potential,AbbVie CEO Richard Gonzalez wants to bring Vraylar to new heights. On Friday, regulators set the next phase of his plan in motion. The FDA approved Vraylar, also known as cariprazine, as an add-on therapy for adults with major depressive disorder (MDD), one of the most common mental disorders in Tags:Business and HealthEndpoints Newsendpts.comFDANewsPharmapopular
Three ways moving on from Aaron Rodgers impacts Packers
Three ways moving on from Aaron Rodgers impacts Packers,Moving on from a franchise quarterback is a challenging situation for any NFL team. Here are three ways the Packers will be impacted if Rodgers has indeed played his last game as a member of the
DOH warns vs eating seafood from oil spill areas
DOH warns vs eating seafood from oil spill areas,The Department of Health warned the public yesterday against eating fish and other seafood from areas affected by the oil spill.
The post DOH warns vs eating seafood from oil spill areas appeared first
Washington turns to Wall Street to help rescue dying bank
Washington turns to Wall Street to help rescue dying bank,In a scene reminiscent of the last financial crisis, the federal government turned to Wall Street this week for help with a blossoming emergency in the banking sector
Isn’t it ironic that Mercury, the planet closest to the Sun, has ice on its poles?,Mercury has closer encounters with the Sun than any other planet in the solar system. It seems that such a planet would be doomed to turn into another Arrakis, especially after billions of years of being scorched by radiation. Tags:iceInterviewsMercuryNewsScienceSunSYFY Official SiteSYFY WIRE Blog Postsyfy.comSYFYWIRE
Full trailer for 'Strange New Worlds' feels like old school 'Star Trek' adventure fans know and love,It's been almost three years since we've seen Anson Mount play Captain Christopher Pike in a Star Trek series. Mount's version of the character — a figure dating back to Star Trek's original unaired pilot episode nearly 60 years ago — was a major player in the second season of Discovery, and popped up again in the Short Treks anthology series. Both those appearances came to a halt in 2019. Tags:Anson MountNewsParamountStar TrekStar Trek Strange New WorldsSYFY Official SiteSYFY WIRE Blog Postsyfy.comSYFYWIRETrailerstv
/cdn.vox-cdn.com/uploads/chorus_asset/file/19941499/1221032041.jpg.jpg "Taika Waititi will direct and co-write a new Star Wars movie")
